6K9 Stock Chart & Stats
€0.48
€0.03(5.70%)
At close: 4:00 PM EDT
€0.48
€0.03(5.70%)
Day’s Range― - ―
52-Week Range€0.42 - €3.12
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€47.75M
Enterprise Value€195.14
Total Cash (Recent Filing)€42.99M
Total Debt (Recent Filing)€244.99K
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Nov 11, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding91,879,170
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.63Price Target Upside657.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
T-cell Engager Pipeline FocusContext’s explicit strategy to build next-generation T cell engagers for solid tumors aligns the company with a durable, fast-growing oncology segment. Focusing on validated tumor antigens and selective TCE designs supports long-term differentiation, partner interest, and optionality across indications and combinations.
Positive Phase 1 CTIM-76 DataInterim positive efficacy and safety data for CTIM-76 materially de-risks a lead clinical asset, strengthening development prospects. Durable impact includes improved likelihood of advancing to later trials, better partner licensing leverage, and higher probability of clinical milestones that drive future strategic choices.
Full Rights Secured To CT-202Acquiring irrevocable, royalty-free rights to CT-202 removes counterparty termination and royalty burdens, improving long-term economics and decision autonomy. This structural control reduces future cash outflows, accelerates partnering or development choices, and preserves upside for shareholders and license strategy.
Bears Say
Pre-revenue With Widening LossesContext remains pre-revenue and has materially larger operating losses over recent periods. Persistent negative earnings mean the company must rely on external financing to fund development, increasing execution risk and limiting the ability to self-fund trials or commercial activities absent partnerships or dilution events.
Accelerating Cash Burn And Equity ErosionOperating cash flow and free cash flow have deteriorated, and shareholder equity has declined steeply, signaling rising financing dependency. This structural cash-burn profile compresses runway, raises dilution risk, and constrains strategic flexibility for multi-year clinical programs without new capital or deal-making.
Nasdaq Minimum Bid-price NoticeA Nasdaq deficiency notice creates a material listing risk and can force remedial corporate actions (reverse split, appeals, or other measures). Such actions can distract management, affect investor perception, complicate equity raises, and introduce execution and governance uncertainty over the medium term.
Context Therapeutics News
6K9 FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was €0.42 and its highest was €3.12 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is €47.75M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 96 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Aug 05, 2026. The company reported -€0.13 earnings per share for the quarter, missing the consensus estimate of -€0.08 by -€0.05.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.08.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 91,879,170 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -€0.13 in its last earnings report, missing expectations of -€0.08. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in DE:6K9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Context Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.63 (657.13% Upside)
€3.63 (657.13% Upside)
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.69%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
6K9 Stock 12 Month Forecast
Average Price Target
€3.63
▲(657.13% Upside)